Daniel C. Chambers

Has grant

Country flagAustralia

Research Interests

Explore related searches

Contact this professor

Get a free first email built on one of their papers, ready for you to edit and send yourself.

Recent Grants

Grant: Close

The SiroSkin study: A multi-centre randomised double-blind placebo-controlled trial of 1% topical sirolimus in the chemoprevention of facial squamous cell carcinomas in solid organ transplant recipients

Open Date: 2021-01-01

Close Date: 2024-01-01

Grant: Close

Silicosis - Harnessing new ideas to conquer the re-emergence of an ancient lung disease - The SHIELD Study

Open Date: 2021-01-01

Close Date: 2024-01-01

Grant: Close

The TELO-SCOPE study: Attenuating Telomere Attrition with Danazol. Is there Scope to Dramatically Improve Health Outcomes for Adults and Children with Pulmonary Fibrosis? (2020–2025)

Open Date: 2020-01-01

Close Date: 2025-01-01

Grant: Close

Silicosis – Harnessing new Ideas to conquer the re-Emergence of an ancient Lung Disease -The SHIELD Study

Open Date: 2019-01-01

Close Date: 2019-01-01

Grant: Close

Ambulatory oxygen for interstitial lung disease

Open Date: 2018-01-01

Close Date: 2022-01-01

Articles (10)

Year:

2023

Year:

2022

Background and Objective Identification of an exposure is integral to the diagnosis, management, and prognostication of chronic hypersensitivity pneumonitis (CHP). Standardized questionnaires may aid in the identification of exposures, however, there currently are no evidence‐based patient‐validated questionnaires available. Key qualifiers (including duration and frequency) which indicate exposure relevance are also poorly defined. This study assessed the use of a standardized CHP exposure questionnaire in the identification of exposures and diagnostic confidence of CHP. Methods People with a multi‐disciplinary meeting (MDM) diagnosis from five Australian interstitial lung disease (ILD) expert centres who provided informed consent were included. Participants completed a previously developed standardized CHP Exposure Questionnaire. Responses were collected with the participant's MDM data, including diagnosis, diagnostic confidence, and clinician‐elicited exposures. Results One hundred thirty participants (IPF = 58, CHP = 24, CTD‐ILD = 17, unclassifiable = 19, other = 12) were included. In 33% of CHP participants, a standardized questionnaire elicited an exposure where the clinician did not. 63% of these had provisional low confidence CHP; and an exposure history would have increased the diagnostic confidence in these cases. Using the standardized questionnaire, 96% of CHP participants reporting any exposure, compared with 75% of non‐HP ILD participants. CHP participants were 3.5 times more likely ( p = 0.004) to report their symptoms improved on avoidance, and 2.3 times more likely ( p = 0.018) to report daily frequent exposure, compared with non‐HP ILDs. Conclusion A standardized questionnaire which elicits exposure characteristics in addition to presence or absence of relevant exposures can increase the diagnostic confidence of CHP and reduce the proportion of antigen‐indeterminate CHP.

Year:

2022

Year:

2022

Year:

2022

Year:

2022

Year:

2022

Year:

2022

Year:

2022

Year:

2022

Collaborators (6)

Magnus Ekström

-

SWEDEN
View details

Michael Harhay

Assistant Professor

University of Pennsylvania

UNITED STATES
View details

Adam Frankel

University of Queensland

AUSTRALIA
View details

Ian Glaspole

-

AUSTRALIA
View details

John Mackintosh

-

AUSTRALIA
View details

Dusan Ilic

University of Newcastle Australia

AUSTRALIA
View details
ApplyKite TwinLearns as you apply

Make your next move.

Prepare your application

Review drafts before you send them.